In stage II/III node positive patients with driver mutations positive NSCLC who are not surgical candidates and are unlikely to tolerate concurrent chemotherapy and radiation, would you consider radiation alone, TKI alone, or would you ever consider TKI + RT?

Topics: Radiation Oncology • Thoracic Malignancies • Medical Oncology • Targeted therapies

What would be the treatment duration if using oral TKI?

Answer from: Medical Oncologist at Community Practice

I am not aware of any data in this regard. Recently, we treated a 78-year-old female patient with MET exon 14 skipping mutation NSCLC with bilateral mediastinal and bilateral supraclavicular lymph node involvement on radiology scans. We were concerned about her ability to tolerate concurrent chemoth...

Comments

Medical Oncologist at Emory University School of Medicine
Very nice approach. I am curious to know about you...

Related Questions